{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:27:05Z","timestamp":1791070025554,"version":"4.1.0"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Boston Scientific and Novartis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The impact of sudden cardiac death (SCD) in heart failure (HF) patients is important and prevention of SCD is a reasonable and clinically justified endpoint if associated with a reduction in all-cause mortality.<\/jats:p>\n               <jats:p>According to literature, in HF with reduced ejection fraction, only three classes of agents were found effective in reducing SCD and all-cause mortality: beta-blockers, mineralcorticoid receptor antagonists and, more recently, angiotensin-receptor neprilysin-inhibitors. In the PARADIGM trial that tested sacubitril\/valsartan vs. enalapril, the 20% relative risk reduction in cardiovascular deaths obtained with sacubitril\/valsartan was attributable to reductions in the incidence of both SCD and death due to HF worsening and this effect can be added to the known positive effect of implantable cardioverter-defibrillators in appropriately selected patients.<\/jats:p>\n               <jats:p>In order to maximize the implementation of all the available treatments, patients with HF should be included in virtuous networks with a dialogue between all the physician involved, with commitment by all these physicians for appropriate decision-making on application of pharmacological and device treatments according to available evidence, as well as commitment for drug titration before and after device implant, taking advantage from remote monitoring, and with the safety of back up device therapy when indicated. There are potential synergistic effects of drug therapy, with all the therapies acting on neuro-hormonal and sympathetic activation, but specifically with sacubitril\/valsartan, and device therapy, in particular cardiac resynchronization therapy, with added incremental benefits on positive cardiac remodelling, prevention of HF progression, and prevention of ventricular tachyarrhythmias.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwaa015","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T04:13:55Z","timestamp":1609474435000},"page":"110-123","source":"Crossref","is-referenced-by-count":28,"title":["Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"first","affiliation":[{"name":"Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Largo del Pozzo 71, 41121 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Ponti","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Circolo Hospital, Universit\u00e0 degli Studi dell'Insubria, Via Ravasi, 2, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5394-1312","authenticated-orcid":false,"given":"Federico","family":"Guerra","sequence":"additional","affiliation":[{"name":"Cardiology and Arrhythmology Clinic, Marche Polytechnic University, University Hospital \u2018Ospedali Riuniti\u2019, Via Lodovico Menicucci, 6, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-6218","authenticated-orcid":false,"given":"Pietro","family":"Palmisano","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u2018Card. G. Panico\u2019 Hospital, Via Papa Pio X, 4, 73039 Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Zanotto","sequence":"additional","affiliation":[{"name":"UFS Cardiologia Interventistica \u2013 Cardiologia Ospedale Mater Salutis, Via Carlo Gianella, 1, 37045 Legnago, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa di Elettrofisiologia, Studio e Terapia delle Aritmie, Azienda Ospedaliera dei Colli \u2013 Monaldi, Via Leonardo Bianchi, 80131, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Pietro","family":"Ricci","sequence":"additional","affiliation":[{"name":"Centro CardioAritmologico, via Alessandro Poerio 91, 00152, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2021032312263351500_zwaa015-B1","volume-title":"Circulation","author":"Myerburg","year":"1992"},{"key":"2021032312263351500_zwaa015-B2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1472-8206.2010.00853.x","article-title":"Role of drugs and devices in patients at risk of sudden cardiac death","volume":"24","author":"Boriani","year":"2010","journal-title":"Fundam Clinical Pharmacol"},{"key":"2021032312263351500_zwaa015-B3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2021032312263351500_zwaa015-B4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2047487318821772","article-title":"Prevention: from the cradle to the grave and beyond","volume":"26","author":"Dendale","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2021032312263351500_zwaa015-B5","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jacc.2017.07.778","article-title":"Defibrillation for ventricular fibrillation","volume":"70","author":"Nichol","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"Hjalmarson","year":"1999","journal-title":"Lancet"},{"key":"2021032312263351500_zwaa015-B7","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/eurheartj\/ehz553","article-title":"What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?","volume":"41","author":"Packer","journal-title":"Eur Heart J"},{"key":"2021032312263351500_zwaa015-B8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/19491034.2018.1506680","article-title":"Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes","volume":"9","author":"Boriani","year":"2018","journal-title":"Nucleus"},{"key":"2021032312263351500_zwaa015-B9","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-020-09933-z","article-title":"Emerging concepts in arrhythmogenic dilated cardiomyopathy","author":"Zegkos","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2021032312263351500_zwaa015-B10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2021032312263351500_zwaa015-B11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10741-018-9679-y","article-title":"Pharmacological treatments for heart failure with preserved ejection fraction\u2014a systematic review and indirect comparison","volume":"23","author":"Bonsu","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2021032312263351500_zwaa015-B12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021032312263351500_zwaa015-B13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B14","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2261-13-52","article-title":"Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials","volume":"13","author":"Al-Gobari","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"2021032312263351500_zwaa015-B15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021108","article-title":"Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews","volume":"8","author":"Al-Gobari","year":"2018","journal-title":"BMJ Open"},{"key":"2021032312263351500_zwaa015-B16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA J Am Med Assoc"},{"key":"2021032312263351500_zwaa015-B18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"2021032312263351500_zwaa015-B19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2021032312263351500_zwaa015-B20","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B21","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJM198008073030607","article-title":"Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings","volume":"303","author":"Mirowski","year":"1980","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B23","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia","volume":"335","author":"Moss","year":"1996","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B24","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","article-title":"A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias","volume":"337","author":"McAnulty","year":"1997","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B25","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1056\/NEJM199912163412503","article-title":"A randomized study of the prevention of sudden death in patients with coronary artery disease","volume":"341","author":"Buxton","year":"1999","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.CIR.101.11.1297","article-title":"Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone","volume":"101","author":"Connolly","year":"2000","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.CIR.102.7.748","article-title":"Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH)","volume":"102","author":"Kuck","year":"2000","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B28","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur Heart J"},{"key":"2021032312263351500_zwaa015-B29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B30","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B32","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":"Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B33","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMoa0901889","article-title":"Defibrillator implantation early after myocardial infarction","volume":"361","author":"Steinbeck","year":"2009","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/joa3.12017","article-title":"Implantable cardioverter defibrillator in nonischemic cardiomyopathy: a systematic review and meta-analysis","volume":"34","author":"Khan","year":"2018","journal-title":"J Arrhythm"},{"key":"2021032312263351500_zwaa015-B35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ejhf.1080","article-title":"Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies","volume":"20","author":"Boriani","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2021032312263351500_zwaa015-B37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ejhf.509","article-title":"Cardiac device therapy in patients with left ventricular dysfunction and heart failure: \u2018real-world\u2019 data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital)","volume":"18","author":"Boriani","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2021032312263351500_zwaa015-B38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ejhf.743","article-title":"Patient outcome after implant of a cardioverter defibrillator in the \u2018real world\u2019: the key role of co-morbidities","volume":"19","author":"Boriani","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2021032312263351500_zwaa015-B39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":"Cardiac-resynchronization therapy in heart failure with a narrow QRS complex","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B40","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":"Cardiac resynchronization in chronic heart failure","volume":"346","author":"Abraham","year":"2002","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B41","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.289.20.2685","article-title":"Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial","volume":"289","author":"Young","year":"2003","journal-title":"J Am Med Assoc"},{"key":"2021032312263351500_zwaa015-B42","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0735-1097(03)01042-8","article-title":"Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias","volume":"42","author":"Higgins","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B43","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1161\/01.CIR.0000146336.92331.D1","article-title":"Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure","volume":"110","author":"Abraham","year":"2004","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B44","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B45","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B46","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B47","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa1210356","article-title":"Biventricular pacing for atrioventricular block and systolic dysfunction","volume":"368","author":"Curtis","year":"2013","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2018.01.039","article-title":"Cardiac resynchronization therapy: how did consensus guidelines from Europe and the United States evolve in the last 15 years?","volume":"261","author":"Boriani","year":"2018","journal-title":"Int J Cardiol"},{"key":"2021032312263351500_zwaa015-B49","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/europace\/eut206","article-title":"ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association","volume":"15","year":"2013","journal-title":"Europace"},{"key":"2021032312263351500_zwaa015-B50","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/europace\/euz055","article-title":"EHRA White Paper: knowledge gaps in arrhythmia management\u2014status 2019","volume":"21","year":"2019","journal-title":"Europace"},{"key":"2021032312263351500_zwaa015-B51","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/CIRCULATIONAHA.119.043012","article-title":"Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish Heart Failure Registry","volume":"140","author":"Schrage","year":"2019","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B52","article-title":"Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study","year":"2020","journal-title":"Eur Heart J."},{"key":"2021032312263351500_zwaa015-B53","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.115.015677","article-title":"Use of the wearable cardioverter defibrillator in high-risk cardiac patients data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II registry)","volume":"132","author":"Kutyifa","year":"2015","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B54","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","article-title":"Wearable cardioverter-defibrillator after myocardial infarction","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jce.14404","article-title":"Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and per-protocol analyses","volume":"31","author":"Olgin","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2021032312263351500_zwaa015-B56","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B57","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"2021032312263351500_zwaa015-B58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","year":"2015","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/europace\/euy110","article-title":"European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Card","volume":"21","year":"2019","journal-title":"Europace"},{"key":"2021032312263351500_zwaa015-B60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2021032312263351500_zwaa015-B611","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1177\/2047487316653709","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR","volume":"23","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2021032312263351500_zwaa015-B62","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212","article-title":"Effects of sacubitril\/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy","volume":"9","author":"Okumura","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2021032312263351500_zwaa015-B63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego","year":"2018","journal-title":"Heart Rhythm"},{"key":"2021032312263351500_zwaa015-B64","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2021032312263351500_zwaa015-B65","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2021032312263351500_zwaa015-B67","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.amjcard.2014.03.049","article-title":"Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the national cardiovascular data registry during the years 2006 to 2008","volume":"113","author":"Schneider","year":"2014","journal-title":"Am J Cardiol"},{"key":"2021032312263351500_zwaa015-B68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ehjcvp\/pvv016","article-title":"Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival","volume":"1","author":"Witt","year":"2015","journal-title":"Eur Hear J - Cardiovasc Pharmacother"},{"key":"2021032312263351500_zwaa015-B69","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2015.12.046","article-title":"Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation","volume":"67","author":"Roth","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B70","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/europace\/eux206","article-title":"Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator","volume":"20","author":"Burri","year":"2018","journal-title":"Europace"},{"key":"2021032312263351500_zwaa015-B71","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jchf.2016.12.011","article-title":"A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study","volume":"5","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2021032312263351500_zwaa015-B72","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ehf2.12394","article-title":"Preliminary experience with the multisensor HeartLogic algorithm for heart failure monitoring: a retrospective case series report","volume":"6","author":"Capucci","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2021032312263351500_zwaa015-B73","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004478","article-title":"Waiting period before implantable cardioverter-defibrillator implantation in newly diagnosed heart failure with reduced ejection fraction: a window of opportunity","volume":"10","author":"DeFilippis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2021032312263351500_zwaa015-B74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.amjcard.2011.10.033","article-title":"How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with \u2018SCD-HeFT Criteria?","volume":"109","author":"Zecchin","year":"2012","journal-title":"Am J Cardiol"},{"key":"2021032312263351500_zwaa015-B75","doi-asserted-by":"crossref","first-page":"204748731987895","DOI":"10.1177\/2047487319878953","article-title":"Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis","author":"Perera","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2021032312263351500_zwaa015-B76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijcard.2017.02.015","article-title":"Effectiveness of a management program for outpatient clinic or remote titration of beta-blockers in CRT patients: the RESTORE study","volume":"236","author":"D\u2019Onofrio","year":"2017","journal-title":"Int J Cardiol"},{"key":"2021032312263351500_zwaa015-B77","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"21","author":"Kapelios","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021032312263351500_zwaa015-B78","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2017.1413","article-title":"Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction secondary analysis of the sudden cardiac death in heart failure trial","volume":"2","author":"Adabag","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2021032312263351500_zwaa015-B79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.017","article-title":"The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients","volume":"201","author":"Friedman","year":"2018","journal-title":"Am Heart J"},{"key":"2021032312263351500_zwaa015-B80","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jacc.2015.05.057","article-title":"Changes in follow-up left ventricular ejection fraction associated with outcomes in primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy device recipients","volume":"66","author":"Zhang","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B81","article-title":"Outcomes after implantable cardioverter-defibrillator generator replacement for primary prevention of sudden cardiac death","volume":"9","year":"2016","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2021032312263351500_zwaa015-B82","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa071098","article-title":"Prognostic importance of defibrillator shocks in patients with heart failure","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"2021032312263351500_zwaa015-B83","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.hrthm.2016.06.007","article-title":"Implantable cardioverter-defibrillator programming and electrical storm: results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD)","volume":"13","author":"Guerra","year":"2016","journal-title":"Heart Rhythm"},{"key":"2021032312263351500_zwaa015-B84","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/europace\/euu298","article-title":"Electrical storm and heart failure worsening in implantable cardiac defibrillator patients","volume":"17","author":"Guerra","year":"2014","journal-title":"Europace"},{"key":"2021032312263351500_zwaa015-B85","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/CIRCULATIONAHA.118.034755","article-title":"Is sacubitril\/valsartan (also) an antiarrhythmic drug?","volume":"138","author":"Sarrias","year":"2018","journal-title":"Circulation"},{"key":"2021032312263351500_zwaa015-B86","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/europace\/euq316","article-title":"Management of patients receiving implantable cardiac defibrillator shocks Recommendations for acute and long-term patient management","volume":"12","author":"Braunschweig","year":"2010","journal-title":"Europace"},{"key":"2021032312263351500_zwaa015-B87","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/jcm9041111","article-title":"The effect of sacubitril\/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator","volume":"9","author":"Russo","year":"2020","journal-title":"J Clin Med"},{"key":"2021032312263351500_zwaa015-B88","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/europace\/eux166","article-title":"Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD)","volume":"20","year":"2018","journal-title":"Europace"},{"key":"2021032312263351500_zwaa015-B89","doi-asserted-by":"crossref","first-page":"e007430","DOI":"10.1161\/CIRCEP.119.007430","article-title":"Compelling first-line drug and device therapies for the prevention of sudden death in patients with chronic heart failure and a reduced ejection fraction who are candidates for an implantable cardioverter-defibrillator","volume":"12","author":"Packer","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2021032312263351500_zwaa015-B90","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2021032312263351500_zwaa015-B91","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2003.05.016","article-title":"Cardiac resynchronization by pacing: an electrical treatment of heart failure","volume":"94","author":"Boriani","year":"2004","journal-title":"Int J Cardiol"},{"key":"2021032312263351500_zwaa015-B92","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2014.06.1178","article-title":"20 years of cardiac resynchronization therapy","volume":"64","author":"Leyva","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B93","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jacc.2008.10.032","article-title":"Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up","volume":"53","author":"Ypenburg","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B94","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jacc.2017.11.020","article-title":"Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block","volume":"71","author":"Sze","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021032312263351500_zwaa015-B95","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ejhf.470","article-title":"Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a meta-analysis of randomized controlled trials in patients with heart failure","volume":"18","author":"Klersy","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2021032312263351500_zwaa015-B96","article-title":"Prospective evaluation of the multisensor HeartLogic algorithm for heart failure monitoring","year":"2020","journal-title":"Clin Cardiol"},{"key":"2021032312263351500_zwaa015-B97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000486410","article-title":"Ventricular arrhythmic storm after initiating sacubitril\/valsartan","volume":"139","author":"Vicent","year":"2018","journal-title":"Cardiology"},{"key":"2021032312263351500_zwaa015-B98","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000496737","article-title":"Electrical storm after initiating sacubitril\/valsartan: arrhythmic paradox","volume":"142","author":"Okutucu","year":"2019","journal-title":"Cardiology"},{"key":"2021032312263351500_zwaa015-B99","doi-asserted-by":"crossref","first-page":"204748732091566","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","author":"Gatti","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2021032312263351500_zwaa015-B100","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/europace\/eut416","article-title":"Awareness of indications for device therapy among a broad range of physicians: a survey study","volume":"16","author":"H\u00fcbinette","year":"2014","journal-title":"Europace"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/1\/110\/36669545\/zwaa015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/1\/110\/36669545\/zwaa015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T12:27:46Z","timestamp":1616502466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/28\/1\/110\/6039464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaa015","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,12,16]]}}}